COVID-19 vaccine trial with two antimalarial drugs - chloroquine and hydroxychloroquine has begun in the UK's Brighton and Oxford. The trial is open to anyone delivering direct care to coronavirus patients in the UK.

‘COVID-19 vaccine trial with two antimalarial drugs - chloroquine and hydroxychloroquine has begun in the UK's Brighton and Oxford.’

They will be given either hydroxychloroquine or a placebo for three months. 




These are the first of a planned 25 UK sites, with results expected by the end of the year.
The trial is open to anyone delivering direct care to coronavirus patients in the UK, as long as they have not been diagnosed with COVID-19.
It will test whether the drugs can prevent healthcare workers exposed to the virus from contracting it.
One of the study's leaders, Professor Nicholas White at the University of Oxford said: "We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19."
Advertisement
"A widely available, safe and effective vaccine may be a long way off," the BBC quoted Professor Martin Llewelyn from Brighton and Sussex Medical School, who is also leading the study.
Advertisement
Source-IANS